Single-agent docetaxel (Taxotere) has been shown to be highly active in metastatic breast cancer, with an overall response rate of 47%, median time to progression of 4 months, and survival of 10 months when administered as
Stephen Chan, MD
Advertisement
Articles by Stephen Chan, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer
2
FDA ODAC Votes Yes to Capivasertib for PTEN-Deficient Metastatic HSPC
3
FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer
4
Targeting KRAS in Pancreatic Cancer: What Is Daraxonrasib’s Mechanism of Action?
5